ERBB2 and breast carcinoma: Notably, combining ICIs and angiogenesis inhibitors based on chemotherapy has a better effect than adding ICIs or angiogenesis inhibitors alone in NSCLC and refractory mCRC, and it also shows the efficacy of combining ICIs with PARP inhibitors plus chemotherapy in HER2-negative breast cancer [54,58,87].